Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37478 NATERA, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 01-0894487 (State or Other ...

| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |--------------|-------|-------|-------|-------|-------|-------|-----------------|-------|-------|-------| | | | | | | | | | | | | | | | | | × | × | × | × × | | × | | | 8 natera | | | | × | | | X X X X X X | | | | | | | | | × | | | X X X X X X | | | | | | | | | × | | | x x x x | | × | | | | | | | × | | | × × × × | | × | | | | | | | × | | | X X X X X X X X | | | | | | | | | × | | | × × × × × × × × | | | | | | | | | × | | | × × × × × × × × | ...

Natera, Inc. (NASDAQ:NTRA) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Michael Brophy - Chief Financial Officer Steve Chapman - Chief Executive Officer Solomon Moshkevich - General Manager, Oncology Conference Call Participants Tejas Savant - Morgan Stanley Stephanie Yan - Cowen Catherine Schulte - Baird Matt Sykes - Goldman Sachs Puneet Souda - SVB Securities Operator Welcome to Natera???s 2022 First Quarter Financial Results Conference Call. At this time, all participants ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37478 NATERA, INC. (Exact Name of Registrant as Specified in Its Charter) 13011 McCallen Pass Building A Suit ...

Natera, Inc. (NASDAQ:NTRA) Q4 2021 Earnings Conference Call February 24, 2022 4:30 PM ET Company Participants Michael Brophy - Chief Financial Officer Steve Chapman - Chief Executive Officer Solomon Moshkevich - General Manager of Oncology & Transplant Conference Call Participants Tejas Savant - Morgan Stanley Puneet Souda - SVB Leerink Tycho Peterson - JPMorgan Catherine Schulte - Baird Max Masucci - Cowen & Company Mark Massaro - BTIG Dan Leonard - Wells Fargo Alex Nowak - Craig-Hallum Capital Group Kyle ...

8 natera × × × × × × × × × × × × × × × × × × Ⅹ Ｘ × × × × × × × × × × X X X X X X X × × Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ⅹ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Natera, Inc. Investor presentation Fourth Quarter 2021 Earnings Call Safe harbor statement This presentation contains forward-looking statements under the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding our market opportunity, our pro ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37478 NATERA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 01-0894487 State or Other Juris ...

8 natera Natera, Inc. Investor presentation JPM 2022 Ⅹ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ × × × × × × × × Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Safe harbor statement This presentation contains forward-looking statements under the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding our market opportunity, our proposed products and la ...

| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |--------------|-------|-------|-------|-------------------|-------|-------|-------|-------|-----------------|-------| | | | | | | | | | | | | | | | | | × × | | | × × × | | × | | | natera | | | | × | | | | | X X X X X X X | | | | | | | × | | | | | X X X X X X X | | | | | | | × | | | | | X X X X X X | | | | | | | × | | | | | X X X X X X X | | | | | | | × | | | | | X X X X X X X X | | | | | | | × | | | | | × × × × × × × × | | | | | | | × × × ...

Natera, Inc. (NASDAQ:NTRA) Q3 2021 Earnings Conference Call November 4, 2021 4:30 PM ET Company Participants Michael Brophy - Chief Financial Officer Steve Chapman - Chief Executive Officer Solomon Moshkevich - General Manager of Oncology & Transplant Conference Call Participants Tejas Savant - Morgan Stanley Tycho Peterson - JPMorgan Puneet Souda - SVB Leerink Catherine Schulte - Baird Alex Nowak - Craig-Hallum Capital Group Mark Massaro - BTIG Operator Welcome to Natera's 2021 Third Quarter Financial Resu ...